Found 15 hodgkin lymphoma trials
A listing of hodgkin lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 33423 A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma (Lumin
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
CILT + HD-tDCS as a Potential Treatment for Primary Progressive Aphasia
Phase 2
Primary Progressive Aphasia, or PPA, is a neurodegenerative disease that affects language abilities. A person with PPA may have difficulties speaking, understanding speech, reading, or writing, and these difficulties worsen over time.The purpose of this study is to determine whether a form of non-invasive brain stimulation called High-definition Transcranial Direct …
UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Phase 1
Non-Hodgkin lymphoma is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).
Biogen 232SM303
This study will evaluate HD nusinersen in participants previously treated with risdiplam who may not be receiving the optimal benefit from treatment because they have reached the dose ceiling of 5 mg.This Phase 3b, open-label, single-arm, interventional study will evaluate the efficacy and safety of HD nusinersen in nonambulatory participants …
Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma
Patients with plasmablastic lymphoma are potential participants of this research trial. Patients with a type of B-cell non-Hodgkin lymphoma (NHL) will be invited from Penn Medicine practices. This research study is designed to test the safety of daratumumab, a drug added to the standard lymphoma treatment when given to individuals …
11 - 15 of 15
- 1
- 2
